Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diffuse large B-cell lymphoma (DLBCL)
Pharma
AbbVie and Genmab’s Epkinly combo scores first-line DLBCL win
The results position Epkinly plus R-CHOP as a potential new standard of care in DLBCL.
Donavyn Coffey
Oct 6, 2026 9:11am
AbbVie, Genmab's Epkinly redeems itself in DLBCL
Jun 30, 2026 9:50am
ADC plots 17% staff cuts amid Zynlonta safety concerns
Jun 24, 2026 10:19am
Patient deaths raise questions about ADC's cancer drug Zynlonta
Jun 4, 2026 11:38am
ASCO: Incyte positions Monjuvi combo for first-line DLBCL
May 30, 2026 8:00am
Incyte to seek FDA approval for Monjuvi in front-line DLBCL
Jan 5, 2026 10:40am
